NCT06815432View on ClinicalTrials.gov

GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

December 3, 2025

Primary Completion Date

December 5, 2029

Study Completion Date

December 3, 2044

Conditions
Glioblastoma Multiforme of Brain
Interventions
GENETIC

15.GPC3-CAR T cells

"Four different dosing schedules will be evaluated. The following dose levels will be evaluated:~DL1: 5x10\^6 DL2: 1x10\^7 DL3: 5x10\^7 DL4: 1x10\^8"

Trial Locations (1)

77030

Baylor St. Luke's Medical Center, Houston

All Listed Sponsors
collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

collaborator

Baylor St. Luke's Medical Center

OTHER

lead

Baylor College of Medicine

OTHER